Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function
Nour Zaïmia, Joëlle Obeid, Annie Varrault, et al.
Cell Reports (2023) Vol. 42, Iss. 11, pp. 113326-113326
Open Access | Times Cited: 20

Showing 20 citing articles:

Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes
Hüsün Sheyma Kizilkaya, Kimmie V. Sørensen, Jakob Sture Madsen, et al.
Nature Metabolism (2024) Vol. 6, Iss. 7, pp. 1268-1281
Open Access | Times Cited: 18
GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Ali H. Shilleh, Katrina Viloria, Johannes Broichhagen, et al.
Peptides (2024) Vol. 175, pp. 171179-171179
Open Access | Times Cited: 11
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access | Times Cited: 1
Jejunoileal side-to-side anastomosis as a promising option for type 2 diabetes
Sang Yeoup Lee
World Journal of Diabetes (2025) Vol. 16, Iss. 4
Closed Access
Exploring the functional, protective, and transcriptomic effects of GIP on cytokine-exposed human pancreatic islets and EndoC-βH5 cells
Kristine Henriksen, Anne Jørgensen, Simranjeet Kaur, et al.
Molecular and Cellular Endocrinology (2025), pp. 112522-112522
Open Access
Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers
Jillian Collins, Nikki L. Farnsworth
Diabetologia (2025)
Closed Access
Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types
Liu Liu, Muhammad Rashid, Jürgen Wess
Biochemistry (2025)
Closed Access
Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients
Jheng‐Yan Wu, Wu-Hao Tu, Tsung Yu, et al.
Diabetes Research and Clinical Practice (2025) Vol. 222, pp. 112083-112083
Closed Access
Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics
Zoe Tasma, Michael L. Garelja, Aqfan Jamaluddin, et al.
Pharmacology & Therapeutics (2025), pp. 108846-108846
Open Access
In vitro fermentation characteristics of polysaccharide from Scrophularia ningpoensis and its effects on type 2 diabetes mellitus gut microbiota
Yang Zhao, Juwei Wen, Yu Yang, et al.
PeerJ (2025) Vol. 13, pp. e19374-e19374
Open Access
Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study
Yu-Min Lin, Kuang‐Ming Liao, Tsung Yu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
G protein-coupled receptor-biased signaling: potential drug discovery to facilitate treatment of metabolic diseases
Shengnan Shen, Qiwen Liao, Liwei Gu, et al.
Acta Materia Medica (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 3
Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes
Joon Ho Moon, Hun Jee Choe, Soo Lim
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 6, pp. 669-683
Open Access | Times Cited: 3
The unexpected role of GIP in transforming obesity treatment
Inuk Zandvakili, Diego Pérez–Tilve
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 3
GLP-1R agonist promotes proliferation of neuroendocrine neoplasm cells expressing GLP-1 receptors
Jonathan S. Shilyansky, Casandro J. Chan, S. Xiao, et al.
Surgery (2024), pp. 108943-108943
Closed Access | Times Cited: 3
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
Mette M. Rosenkilde, Peter Lindquist, Hüsün Sheyma Kizilkaya, et al.
Peptides (2024) Vol. 177, pp. 171212-171212
Open Access | Times Cited: 2
Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice
Yuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, et al.
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 2
Variants in PPARD-GLP1R are related to diabetic kidney disease in Chinese Han patients with type 2 diabetes mellitus
Jinfang Song, Yongru Zhuang, Xiaojun Pan, et al.
Heliyon (2024) Vol. 10, Iss. 15, pp. e35289-e35289
Open Access | Times Cited: 1
A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and Glucose-dependent Insulinotropic Polypeptide Receptors
Junmin Jiang, Meifeng Shi, Shuduo Wu, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 1
Does Incretin Agonism Have Sustainable Efficacy?
Sok‐Ja Janket, Miyo K. Chatanaka, Dorsa Sohaei, et al.
Cells (2024) Vol. 13, Iss. 22, pp. 1842-1842
Open Access | Times Cited: 1
Efficacy and safety of different doses of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
Junxia Zhu, Yingjie Huang, Yang Luo, et al.
Research Square (Research Square) (2024)
Open Access
Page 1

Scroll to top